Sara Bayat

Sara Bayat

Auto-generated profile, based on publicly available information

Sara Bayat

Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JKJohannes Knitza
Johannes Knitza
DSDavid Simon
David Simon
ALAntonia Lambrecht
Antonia Lambrecht
CRChristina Raab
Christina Raab
KTKoray TASCILAR
Koray TASCILAR
AHAxel J Hueber
Axel J Hueber
Background: Mobile health (mHealth) defines the support and practice of health care using mobile devices and promises to improve the current treatment situation of patients with chronic diseases. Little is known about mHealth usage and digital preferences of patients with chronic rheumatic diseases. Objective: The aim of the study was to explore mHealth usage, preferences, barriers, and eHealth literacy reported by German patients with rheumatic diseases. Methods: Between December 2018 and January 2019, patients (recruited consecutively) with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis were asked to complete a paper-based survey. The survey included questions on sociodemographics, health characteristics, mHealth usage, eHealth literacy using eHealth Literacy Scale (eHEALS), and communication and information preferences. Results: Of the patients (N=193) who completed the survey, 176 patients (91.2%) regularly used a smartphone, and 89 patients (46.1%) regularly used social media. Patients (132/193, 68.4%) believed that using medical apps could be beneficial for their own health. Out of 193 patients, only 8 (4.1%) were currently using medical apps, and only 22 patients (11.4%) stated that they knew useful rheumatology websites/mobile apps. Nearly all patients (188/193, 97.4%) would agree to share their mobile app data for research purposes. Out of 193 patients, 129 (66.8%) would regularly enter data using an app, and 146 patients (75.6%) would welcome official mobile app recommendations from the national rheumatology society. The preferred duration for data entry was not more than 15 minutes (110/193, 57.0%), and the preferred frequency was weekly (59/193, 30.6%). Medication information was the most desired app feature (150/193, 77.7%). Internet was the most frequently utilized source of information (144/193, 74.6%). The mean eHealth literacy was low (26.3/40) and was positively correlated with younger age, app use, belief in benefit of using medical apps, and current internet use to obtain health information. Conclusions: Patients with rheumatic diseases are very eager to use mHealth technologies to better understand their chronic diseases. This open-mindedness is counterbalanced by low mHealth usage and competency. Personalized mHealth solutions and clear implementation recommendations are needed to realize the full potential of mHealth in rheumatology.

1 October 2025 in RMD Open
Verified
Journal Article
Open access
AAArmin Atzinger
Armin Atzinger
KTKoray TASCILAR
Koray TASCILAR
AKArnd Kleyer
Arnd Kleyer
AHAxel J Hueber
Axel J Hueber
CSChristian Schmidkonz
Christian Schmidkonz
SBSara Bayat
Sara Bayat
Objectives: Activated synovial fibroblasts play a key role in rheumatoid arthritis (RA). Positron emission tomography-CT (PET-CT) using 68g allium-labelled fibroblast activation protein inhibitor (FAPI) allows the detection of FAP-expressing activated fibroblasts in humans in vivo. Herein, this study aimed to investigate whether fibroblast activation already occurs in the pre-clinical phase of RA and whether it is associated with the development of clinical disease. Methods: 68 Ga-FAPI-46 PET-CT was performed in individuals positive for anti-citrullinated protein antibodies (ACPAs) with clinically suspect arthralgia without present or past signs of joint swelling or present or past anti-rheumatic therapy. All participants underwent structured clinical and laboratory evaluations and were followed for the development of RA. Synovial FAPI uptake was quantified and related to demographic characteristics, joint tenderness, ACPA levels and RA development. Findings: Eighteen RA-at-risk individuals (male/female: 7/11; mean age, 47 (SD 14) years) underwent 68 Ga-FAPI-46 PET-CT and were followed for a median of 42 weeks. Five participants (28%) developed RA with a median of 12 weeks (IQR, 11–20), whereas 13 remained disease-free. Total lesion FAPI-uptake (TL-FAPI) was a significant predictor of RA development (HR 4.58, 95% CI 1.38 to 15.22, p=0.013). Increasing TL-FAPI at the joint level was also associated with tenderness (isk ratio 1.14, 95% CI 1.08 to 1.22, p=0.001). Conclusions: The findings in this small RA-at-risk cohort suggest that synovial fibroblast activation occurs early in the disease process of RA and is associated with an increased risk for clinical RA onset. These results warrant further research on FAPI-PET-CT to improve risk assessment for clinical RA onset.

26 March 2025 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
FSFatemeh Salehi
Fatemeh Salehi
SBSara Bayat
Sara Bayat
GSGeorg Schett
Georg Schett
AKArnd Kleyer
Arnd Kleyer
TAThomas Altstidl
Thomas Altstidl
Bjoern EskofierBjoern Eskofier
Bjoern Eskofier
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting peripheral joints. Before clinical diagnosis, individuals may possess certain antibodies and experience discomfort but without specific signs of RA or inflamed joints. This stage is termed “preclinical RA,” as these individuals are at risk of developing the disease. This early stage is difficult to define, necessitating the development of individual risk models. This study aims to estimate the time and risk of RA onset using various survival machine learning models. After identifying the best model, we stratify patients into risk categories and identify key risk factors. Data from 154 anonymized preclinical RA patients were collected and analyzed. Several survival analysis models were evaluated, including Survival Tree, Random Survival Forest, Extreme Gradient Boosting Survival, Linear Multi-Task Model, Neural Multi-Task Model, Support Vector Machines, and Cox Proportional Hazards. The Random Survival Forest model outperformed the others, achieving a mean C-index of 0.798. Using this model, patients were stratified into low-, medium-, and high-risk groups, facilitating personalized scheduling of clinical visits based on RA risk. To enhance model interpretability, SHapley Additive Explanations (SHAP) are employed to identify key risk factors. The baseline level of rheumatoid factor (RF) antibodies is the most significant predictor. Higher levels of anti-cyclic citrullinated peptide (anti-CCP) and RF antibodies at baseline are linked to earlier RA onset. This method provides valuable insights into key factors that might be overlooked in clinical practice and can improve patient management and quality of life for those at risk of developing RA.

21 November 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
SBSara Bayat
Sara Bayat
KTKoray TASCILAR
Koray TASCILAR
DBDaniela Bohr
Daniela Bohr
GKGerhard Krönke
Gerhard Krönke
DSDavid Simon
David Simon
AKArnd Kleyer
Arnd Kleyer
Background Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy. However, real-world data are scarce regarding efficacy and drug persistence for BARI monotherapy (BARI-mono) versus its combination with MTX (BARI-combo). Objective To evaluate efficacy and drug persistence of BARImono compared with BARI-combo in routine clinical practice Methods Patients with RA who were switched to BARI were included in a prospective, monocentric cohort. Demographics, clinical outcomes, adverse events and medication were prospectively recorded every 3 months. Clinical efficacy was measured by DAS-28 ESR while drug persistence was measured as the time on drug. We estimated least-square mean DAS-28 scores over time using linear mixed effects models including time-group interactions. Kaplan-Meier method was used to estimate BARI survival and probability of remission over time. Results 139 patients (98 women; aged 58.4 (12.8) years; mean disease duration of 9.7 years) were included between 2017 and 2021. 46 patients received BARI-combo, 93 patients received BARI-mono. Mean DAS-28 ESR were not significantly but only numerically different between both groups at baseline and multiple timepoints over follow-up. DAS-28 ESR remission was attained at least once upto 48 weeks in 62% and 51% patients in BARI-combo versus BARI-mono group (log-rank p=0.64). Drug persistence was high (69 vs 67% at 48 weeks and 62% vs 56% at 96 weeks) and similar in BARI-combo-treated and BARI-mono-treated patients. b/ts DMARD naïve patients had lower mean DAS-28 scores over the follow-up and attained DAS-28 ESR remission earlier than patients with inadequate response to b/ts DMARDs (p=0.11). BARI was discontinued in 11/139 patients (7.9%) due to adverse effects. Conclusion In routine practice, BARI is effective as monotherapy in case of MTX intolerance with overall high drug persistence rates. No new safety signals were observed.

28 April 2020 in JMIR Preprints
Verified
Preprint
Open access
JKJohannes Knitza
Johannes Knitza
DSDavid Simon
David Simon
ALAntonia Lambrecht
Antonia Lambrecht
CRChristina Raab
Christina Raab
KTKoray TASCILAR
Koray TASCILAR
AHAxel J Hueber
Axel J Hueber
BACKGROUND Mobile health (mHealth) defines the support and practice of health care using mobile devices and promises to improve the current treatment situation of patients with chronic diseases. Little is known about mHealth usage and digital preferences of patients with chronic rheumatic diseases. OBJECTIVE The aim of the study was to explore mHealth usage, preferences, barriers, and eHealth literacy reported by German patients with rheumatic diseases. METHODS Between December 2018 and January 2019, patients (recruited consecutively) with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis were asked to complete a paper-based survey. The survey included questions on sociodemographics, health characteristics, mHealth usage, eHealth literacy using eHealth Literacy Scale (eHEALS), and communication and information preferences. RESULTS Of the patients (N=193) who completed the survey, 176 patients (91.2%) regularly used a smartphone, and 89 patients (46.1%) regularly used social media. Patients (132/193, 68.4%) believed that using medical apps could be beneficial for their own health. Out of 193 patients, only 8 (4.1%) were currently using medical apps, and only 22 patients (11.4%) stated that they knew useful rheumatology websites/mobile apps. Nearly all patients (188/193, 97.4%) would agree to share their mobile app data for research purposes. Out of 193 patients, 129 (66.8%) would regularly enter data using an app, and 146 patients (75.6%) would welcome official mobile app recommendations from the national rheumatology society. The preferred duration for data entry was not more than 15 minutes (110/193, 57.0%), and the preferred frequency was weekly (59/193, 30.6%). Medication information was the most desired app feature (150/193, 77.7%). Internet was the most frequently utilized source of information (144/193, 74.6%). The mean eHealth literacy was low (26.3/40) and was positively correlated with younger age, app use, belief in benefit of using medical apps, and current internet use to obtain health information. CONCLUSIONS Patients with rheumatic diseases are very eager to use mHealth technologies to better understand their chronic diseases. This open-mindedness is counterbalanced by low mHealth usage and competency. Personalized mHealth solutions and clear implementation recommendations are needed to realize the full potential of mHealth in rheumatology.

1 October 2025 in RMD Open
Verified
Journal Article
Open access
ATAlp Temiz
Alp Temiz
KTKoray TASCILAR
Koray TASCILAR
AKArnd Kleyer
Arnd Kleyer
AHAxel J Hueber
Axel J Hueber
FHFabian Hartmann
Fabian Hartmann
SBSara Bayat
Sara Bayat
Background: Janus kinase inhibitors (JAKi), like baricitinib, are used as monotherapy (MONO) and in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. This study aimed to evaluate the long-term efficacy, drug survival and safety of baricitinib MONO versus combination therapy (COMBO) in a prospective cohort of patients with RA. Methods: We analysed data from 219 RA patients initiating baricitinib in a single-centre, prospective observational cohort between 2017 and 2023. Clinical data, patient-reported outcomes and safety events were collected every 3 months. Drug survival was analysed using the Kaplan-Meier method, and longitudinal outcomes were assessed using linear mixed-effects models. Results: The cohort included 219 patients (165 MONO, 54 COMBO) with high baseline disease activity (mean DAS28-ESR 4.0). Both groups showed rapid and sustained clinical improvement, with disease activity stabilising in the low range by 6 months of treatment. One third of the patients (n=72, 33%) achieved Boolean remission, with no significant difference between groups (p=0.35). Median drug survival was 36 months and was similar for both regimens (log-rank p=0.82). Discontinuation due to adverse events occurred in 10.9% of patients. Four thrombotic events were noted, all in patients with pre-existing cardiovascular risk factors, with no new safety signals emerging. Conclusions: In this real-world cohort, baricitinib demonstrated sustained long-term effectiveness, drug survival and an acceptable safety profile. The similar outcomes observed for MONO and COMBO indicate that baricitinib may be used effectively as MONO in patients with RA for whom MTX is not suitable or tolerated.